MAIA

MAIA Biotechnology, Inc. Appoints Joseph F. McGuire as Chief Financial Officer and Provides Corporate Update

Retrieved on: 
星期二, 八月 17, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, MD, University, Growth, Cancer, SEC, Research, AR, Forward-looking statement, MAIA, Patient, FKBP52, Biotechnology, Prostate cancer, PricewaterhouseCoopers, Notre Dame, Breast cancer, View, Dean Witter Reynolds, Pharmaceutical industry, Management

MAIA Biotechnology, Inc. , a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology drugs (MAIA), announced today that it has appointed Joseph F. McGuire as Chief Financial Officer.

Key Points: 
  • MAIA Biotechnology, Inc. , a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology drugs (MAIA), announced today that it has appointed Joseph F. McGuire as Chief Financial Officer.
  • MAIA has also provided a corporate update announcing the creation of a wholly-owned subsidiary in Australia to execute on its global development strategy.
  • Mr. McGuire brings over 30 years of experience to MAIA, having served as Chief Financial Officer for several privately held and publicly traded companies in the health care, financial services, investment, and manufacturing industries.
  • In addition to the appointment of Mr. McGuire as Chief Financial Officer, MAIA also announced today that is has established a wholly owned subsidiary in Australia, MAIA Biotechnology Australia Pty Ltd.

MAIA Biotechnology, Inc. Announces Additions to Executive Team and Board of Directors

Retrieved on: 
星期三, 八月 4, 2021
Biotechnology, General Health, Health, Pharmaceutical, Oncology, Media (communication), Digital, MedImmune, New York University, Book, Insight, Data Analytics Acceleration Library, FKBP4, University of Zambia School of Medicine, Hematology, Strategic planning, Cancer, View, AR, Marketing, Medicine, Internal medicine, Drug development, Hospital, Carol Davila University of Medicine and Pharmacy, Head, Artificial intelligence, Dartmouth, Medical Affairs Bureau, Pharmacyclics, Communication, Therapy, Prudential Financial, MD, SBS, MAIA, HSBC, Growth, Prostate cancer, SBS Swiss Business School, Research, Breast cancer, University, Lead, Vice president, Project, Patient, 2011 New Year Honours (New Zealand), Hematology-Oncology and Stem Cell Transplantation Research Center, Dartmouth–Hitchcock Medical Center, Biotechnology, Yale New Haven Hospital, Forward-looking statement, Pharmaceutical industry

Mihail is a distinguished physician scientist and accomplished drug developer who has brought numerous oncology drugs to patients in need.

Key Points: 
  • Mihail is a distinguished physician scientist and accomplished drug developer who has brought numerous oncology drugs to patients in need.
  • Dr. Obrocea has played an instrumental role in the development and commercialization of numerous drugs, including IMBRUVICA, BESPONSA, and BREYANZI.
  • MAIA cautions that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements.
  • In this release, unless the context requires otherwise, MAIA, Company, we, our, and us refers to MAIA Biotechnology, Inc. and its subsidiaries.